首页> 外国专利> ACID DERIVATIVES 3- (4-PIRIDIN-2-ILAMINO) -BUTIRIL) -2,3,4, 4A, 9, 9A-HEXAHIDRO-1H-3-AZA-FLUOREN-9-IL) ACETIC AND RELATED TRICICLIC INDANILS AS ALFAV BETA3 AND ALFAV AND BETA5 INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER AND THE UNSTABLE ANGINA.

ACID DERIVATIVES 3- (4-PIRIDIN-2-ILAMINO) -BUTIRIL) -2,3,4, 4A, 9, 9A-HEXAHIDRO-1H-3-AZA-FLUOREN-9-IL) ACETIC AND RELATED TRICICLIC INDANILS AS ALFAV BETA3 AND ALFAV AND BETA5 INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER AND THE UNSTABLE ANGINA.

机译:酸衍生物3-(4-PIRIDIN-2-ILAMINO)-丁腈)-2,3,4,4A,9,9A-六氢-1H-3-氮杂-氟-9-IL)乙酸和相关的三氯硝基苯磺酸用于治疗癌症和不稳定型心绞痛的BETA3,ALFAV和BETA5整合素抑制剂。

摘要

A compound of Formula (I): where: R is selected from the group consisting of heterocyclyl and heteroaryl; R1 is one to two substituents selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, -NRARB, and halogen; wherein alkyl and alkoxy are optionally substituted on a terminal carbon with one to three substituents independently selected from the group consisting of halogen, hydroxy, or -NRARB; where RA and RB are substituents independently selected from hydrogen or C1-C6 alkyl; R2 is one to two substituents independently selected from the group consisting of hydrogen, C1-C4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy, -NRCRD, hydroxy, and halogen; wherein alkyl, alkenyl, alkynyl, and alkoxy are optionally substituted on a terminal carbon atom with one to three substituents independently selected from the group of halogen, hydroxy, C1-C4 alkoxy, and RC-RD; where RC and RD are substituents independently selected from hydrogen and C1-C6 alkyl; RC and RD are optionally taken together with the atoms to which they are anchored to form a five to seven member monocyclic ring; Z is selected from the group consisting of -CH2- and -CH-; A is selected from the group consisting of aryl, - CH (CH2) 1-3, and - (CH2) 1-3 provided that when A is - CH (CH2) 1-2- and Z is -CH- a double is formed link between A and Z; B is -NH- when optionally present; m and n are integers from 1 to 3; X is selected from the group consisting of O, S, and two hydrogen atoms; U is independently selected from -CH-, N, or S, provided that no more than one U represents S or N; and that U can only be S when W is not present; W is selected from the group consisting of -CH- and N when optionally present; and enantiomers, diastereoisomers, tautomers, solvates, or pharmaceutically acceptable salts and medicaments thereof.
机译:式(I)的化合物:其中:R选自杂环基和杂芳基; R1是1-2个选自氢,C1-C4烷基,C1-C4烷氧基,羟基,-NRARB和卤素的取代基;其中烷基和烷氧基任选地在末端碳上被1-3个独立地选自卤素,羟基或-NRARB的取代基取代;其中RA和RB是独立地选自氢或C1-C6烷基的取代基; R2是1-2个独立地选自氢,C1-C4烷基,C2-C6烯基,C2-C6炔基,C1-C4烷氧基,-NRCRD,羟基和卤素的取代基;其中烷基,烯基,炔基和烷氧基任选在末端碳原子上被1-3个独立地选自卤素,羟基,C1-C4烷氧基和RC-RD的取代基取代;其中RC和RD是独立地选自氢和C1-C6烷基的取代基; RC和RD以及与它们所锚定的原子一起形成五至七元单环; Z选自-CH 2-和-CH-; A选自芳基,-CH(CH2)1-3和-(CH2)1-3,条件是当A为-CH(CH2)1-2-和Z为-CH-时, A和Z之间形成链接;当任选存在时,B为-NH-; m和n是1至3的整数; X选自由O,S和两个氢原子组成的组;只要不多于一个U代表S或N,U独立地选自-CH-,N或S;当W不存在时,U只能是S;当任选存在时,W选自-CH-和N;及其对映异构体,非对映异构体,互变异构体,溶剂化物或其药学上可接受的盐和药物。

著录项

  • 公开/公告号ES2268584T3

    专利类型

  • 公开/公告日2007-03-16

    原文格式PDF

  • 申请/专利权人 JANSSEN PHARMACEUTICA N.V.;

    申请/专利号ES20040254584T

  • 申请日2004-07-30

  • 分类号A61K31/435;A61K31/4375;A61K31/444;A61K31/506;A61P9/10;A61P35/04;C07D401/12;C07D471/04;

  • 国家 ES

  • 入库时间 2022-08-21 20:54:35

相似文献

  • 专利
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号